Domestic leading enterprise of chronic disease monitoring and management

•Founded in 2010, it is a national high-tech enterprise dedicated to the research, development, production and sales of products for rapid detection of chronic diseases using biosensor technology. Its products cover a comprehensive platform company for the detection and management of blood glucose, blood lipids, glycosylated hemoglobin, blood ketone, uric acid, myocardial infarction, heart failure and other chronic disease indicators. 

•It has been successively recognized as Tianjin Small and Medium sized Science and Technology Enterprise, Tianjin High tech Enterprise, National High tech Enterprise and Tianjin Key Development Product;It has been supported by the National Innovation Fund for many times;Passed ISO13485 quality management system certification and EU CE certification. 

•Mycura series blood glucose meter and matching test paper have been recognized by many hospitals and end users with the characteristics of "accuracy, simplicity and economy", and have 100000+terminals and 200+channel merchants in China. 

•Based on the sales volume in 2021, Mycura Biology has the second market share in the field of blood glucose detection in China. 

•In 2022, SciNova will invest 15 million yuan and coach CITIC Securities.